Clinical Trials Logo

Acute Ischemic Stroke clinical trials

View clinical trials related to Acute Ischemic Stroke.

Filter by:

NCT ID: NCT03702452 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

The Effect and Mechanism of wCST-LL Based Precision Rehabilitation Nursing on Motor Dysfunction After Acute Stroke

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Ischemic stroke is the main cause of disability in the world. More than 70% of stroke patients show various degrees of neural function impairment. Motor rehabilitation in acute phase is beneficial for improving patient's structure and function of corticospinal tract. However, it is difficult to obtain effective rehabilitation during the acute phase of stroke because of the insufficiency of professional rehabilitation therapists in stroke wards in China.The present study is to verify that nursing-directed rehabilitation can compensate for the shortage of professional rehabilitation therapists. Our previous study indicated that nursing-directed motor function rehabilitation provided more obvious effect on stroke patients with a weighted corticospinal tract lesion load (wCST-LL) smaller than 2ml. We assume that implementing rehabilitation nursing based on the wCST-LL can realize nursing-directed, wCST-LL-based precision motor rehabilitation during acute phase of ischemic stroke.The present study is to conduct randomized clinical trial to confirm the effect of nursing-directed precision rehabilitation for motor function in acute stroke patients grouped by wCST-LL, and to evaluate the effect of this precision rehabilitation by using functional scale, and to explore the histopathologic mechanism of the precision rehabilitation nursing by mean of neuroelectrophysiology and neuroimaging examination. This study might provide theoretical support for motor rehabilitation in patients during acute phase of stroke.

NCT ID: NCT03686163 Recruiting - Clinical trials for Acute Ischemic Stroke

Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke

Start date: January 2016
Phase: Phase 4
Study type: Interventional

Stroke remains one of the leading causes of death and adult disability worldwide. Yet, currently, the only accepted treatment for acute ischemic stroke(AIS) is recanalization of occluded arteries. Thrombolysis with tissue plasminogen activator, limited by its narrow therapeutic time window and the concern of hemorrhagic complication, is still uncommon in use. The other approach is to try to impede the ischemic cascade by targeting various components of the cascade that are deemed to be of importance, namely, a neuroprotection strategy. Nerve growth factor (NGF) plays extensive roles in preventing ischemic injury. Besides that, it is also involved in neurogenesis of the central nervous system (CNS). In addition, the levels of NGF protein and messenger RNA significantly decreased in the CNS at the first few hours and returned to normal levels several days later after middle cerebral artery occlusion (MCAO) in animal models. These observed results suggested that NGF was demanded in ischemic brain injury, but endogenous NGF is insufficient for the requirement and delivering exogenous ones will be blocked in entering into the CNS by the blood-brain barrier (BBB). Intracerebroventricular or intracerebral injection of NGF or grafting of NGF-producing cells may be less practicable due to invasiveness and safety concerns. Intranasal (IN) administration is a noninvasive and acceptable delivery strategy for drugs bypassing BBB and can deliver NGF to the CNS, which has been proved to show neuroprotective effects on brain injury. The effects of intranasal NGF in human ischemic stroke is still controversial that need further evaluation.

NCT ID: NCT03680469 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

The Effectiveness of Early Mobilization for Acute Ischemic Stroke Treated With Rt-PA or IA Thrombectomy

Start date: October 2018
Phase: N/A
Study type: Interventional

The purpose of the study will to test the hypothesis that combining early out-of-bed mobilization within 72 hours of stroke onset with treated by intravenous recombinant tissue-type plasminogen activator (IV-rtPA) or endovascular thrombectomy (ET) would result in a greater benefit than standard early rehabilitation within 72 hours of stroke onset with treated by IV-rtPA or ET.

NCT ID: NCT03669653 Recruiting - Clinical trials for Acute Ischemic Stroke

Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke

SERIC-AIS
Start date: September 17, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

NCT ID: NCT03608644 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Predictive Factors of Outcome of Mechanical Thrombectomy After Acute Ischemic Stroke

Start date: October 30, 2018
Phase:
Study type: Observational

Predictive factors of outcome of mechanical thrombectomy after acute ischemic stroke

NCT ID: NCT03601702 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

Start date: September 15, 2018
Phase:
Study type: Observational [Patient Registry]

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

NCT ID: NCT03539445 Recruiting - Clinical trials for Acute Ischemic Stroke

Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment

BAST
Start date: July 17, 2018
Phase: Phase 3
Study type: Interventional

Butylphthalide, as a well-known neuroprotective medication, is a family of compounds initially isolated from the seeds of Apium graveolens Linn, of which active ingredient is dl-3-N-butylphthalide (dl-NBP). With the significant effects of reducing the cerebral ischemic damage and eventually improving patients' clinical outcomes, by the potential mechanisms of promoting microcirculation, as well as releasing oxidative stress, mitochondrial dysfunction and poststroke inflammation, dl-NBP has been widely applied in acute ischemic stroke as an anti-ischemic drug in China since 2002. While with the evolution of using iv. recombinant tissue plasminogen activator(rtPA )and mechanical thrombectomy in acute ischemic stroke(AIS)patients, it is still undefined whether combination therapy with dl-NBP could enhance the curative effect. The primary purpose of this trial is to evaluate the recovery of neurological deficits in AIS patients who receive iv-rtPA and/or mechanical thrombectomy with the a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest 15th to 90th day therapy versus a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and followed by Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest 15th to 90th day therapy.

NCT ID: NCT03529149 Recruiting - Clinical trials for Acute Ischemic Stroke

TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT

Start date: April 8, 2018
Phase: Phase 4
Study type: Interventional

Investigators hypothesized that the precise regulation of blood pressure based on the changes of cerebral blood flow parameters under TCD monitoring can better improve the state of cerebral blood flow, reduce the risk of early neurological deterioration and improve the prognosis of the patients.

NCT ID: NCT03519737 Recruiting - Clinical trials for Acute Ischemic Stroke

Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke

TRUST
Start date: August 17, 2018
Phase: N/A
Study type: Interventional

This is a randomized, placebo controlled, double-blind phase 3 clinical study to evaluate the efficacy and safety of transcranial ultrasound (TUS) using the Sonolysis Headframe as an adjunctive therapy to intravenous (IV) tissue plasminogen activator (tPA) therapy in subjects with acute ischemic stroke that initially present at non-endovascular (EVT) treating hospitals that have established transport services in place to transfer subjects to hospitals capable of performing EVT.

NCT ID: NCT03516227 Completed - Clinical trials for Acute Ischemic Stroke

Effects of Biofeedback in Patients With Acute Cerebral Infarction

Start date: November 9, 2015
Phase: Phase 1
Study type: Interventional

The major aim of this study is to investigate the effects of biofeedback assisted abdominal breathing training on improving the psychological and physiological distress in patients with ACI. In this randomized, controlled, single-blind trial, AIS patients were randomly assigned into experimental and control groups. The experimental group received four HRVBF training sessions. The control group received routine care. Repeated measures of HRV, Mini-Mental Status Examination (MMSE), Hospital Anxiety and Depression Scales (HADS), and Barthel Index for ADLs were collected prior to, and at one, and three months post-intervention.